{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 49,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 36,
  "notes": "The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/20",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.45,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Conversion case study: PNH conversion in three recent country launches",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2e103d1-f73d-48ff-a0bc-b23da7208fac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Accelerating pace of Ultomiris launches globally",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b7a1b4b-df9a-4090-be6d-383c82e07501",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "1. Represents total FDA, MAA submissions, total count does not include additional indication submissions; cumulative filing count 2. Ultomiris patient share average calculated based on data from Germany, UK, Italy, France and Australia. PNH = paroxysmal nocturnal haemoglobinuria; FDA = Food and Drug Administration; MAA = Marketing Authorisation Application; UK = United Kingdom.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64a2b0d3-2ae1-454a-a9f5-9c014a20a40d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Significant market expansion underway, demonstrated rapid conversion upon launch",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c38684c-7e5f-4783-998a-0d060c1f771c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Ultomiris geographic expansion",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efc374ed-49aa-4f50-8d41-b2e7be6062fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "d4d138c4-1c2c-4efe-a6c5-dff987ea83c8",
      "evidence": "Significant market expansion underway, demonstrated rapid conversion upon launch",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 20,
      "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142",
      "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space",
      "position": 2,
      "objective": "What are the key opportunities for AstraZeneca's Rare Disease division",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}